Selective inhibition of systemic anti-OVA IgE production in response to oral pre-treatment with OVA-liposome conjugates.
BACKGROUND
We have previously reported that intraperitoneal injection with OVA-liposome conjugates induces OVA-specific and IgE-selective unresponsiveness in mice.


METHODS
In the present study, the effects of oral pre-treatment with OVA-liposome conjugates or with plain OVA solution on anti-OVA IgG antibody production were investigated in mice after subsequent immunization with alum-adsorbed OVA. Control mice received only the immunization.


RESULTS
The levels of serum anti-OVA IgG antibody in mice receiving oral administration of OVA-liposome were comparable to those in the control mice. However, in mice receiving oral administration of the same dose of plain OVA, levels of serum anti-OVA IgG antibody were significantly lower than those in control mice. Surprisingly, anti-OVA IgE antibody production was completely inhibited in mice receiving oral administration of OVA-liposome conjugates. Splenic CD4(+) T cells of mice receiving oral administration of OVA-liposome and those of control mice produced comparable levels of cytokines, while those of mice receiving oral administration of plain OVA solution produced significantly lower levels of cytokines than those in the other two groups.


CONCLUSIONS
Orally administered OVA-liposome did not affect anti-OVA IgG production but did inhibit anti-OVA IgE antibody production, while orally administered OVA solution inhibited production of both IgG and IgE antibodies. These results suggest that antigen-liposome conjugates can possibly be orally administered in order to control antigen-specific IgE antibody production, without affecting IgG antibody production.
Naito
Seishiro
S
Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Musashimurayama, Tokyo, Japan.
Taneichi
Maiko
M
Kato
Hiroshi
H
Tanaka
Yuriko
Y
Ami
Yasushi
Y
Suzaki
Yuriko
Y
Mori
Masahito
M
Nakano
Yoshio
Y
Yamamura
Hiroyuki
H
Morokuma
Kazunori
K
Ohkuma
Kunio
K
Miyake
Hidekazu
H
Kiniwa
Mamoru
M
Komuro
Katsutoshi
K
Uchida
Tetsuya
T
D000284:Administration, Oral; D000485:Allergens / Q000008:administration & dosage; D000534:Alum Compounds / Q000008:administration & dosage; D000818:Animals; D000918:Antibody Specificity; D016207:Cytokines / Q000096:biosynthesis; D005260:Female; D007115:Immunization Schedule; D007073:Immunoglobulin E / Q000096:biosynthesis* / Q000097:blood; D007074:Immunoglobulin G / Q000096:biosynthesis / Q000097:blood; D008081:Liposomes; D051379:Mice; D008807:Mice, Inbred BALB C; D010047:Ovalbumin / Q000008:administration & dosage* / Q000276:immunology*
D000485:Allergens; D000534:Alum Compounds; D016207:Cytokines; D007074:Immunoglobulin G; D008081:Liposomes; C041524:aluminum sulfate; D007073:Immunoglobulin E; D010047:Ovalbumin